603669.SH
灵康药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.39
−1.64%Year over year
Reported trailing growth
- Revenue
- +1.7%
- EBITDA
- —
- EBIT
- -34.9%
- EPS
- -28.7%
- Free cash flow
- -39.9%
- Operating cash flow
- -43.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.7%
- EBITDA
- -76.8%
- EBIT
- -52.2%
- Net income
- -47.8%
- EPS
- -50.0%
- Free cash flow
- -13.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026